Current Neuro-Oncology
Volume
26 Number 10
31 May 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 10, 31 May
Biswas
K, Agrawal S, Gupta P, Arora R.
Evaluation
of risk factors for postoperative neurologic intensive care
admission after brain tumor craniotomy: A single-center
longitudinal study.
J
Anaesthesiol Clin Pharmacol.
2024 May 16;40(2):217-227. doi:
10.4103/joacp.joacp_323_22. PMID:
38919448. Observational study. ˍ
Hampe L, Daumoine S, Limagne E, Roussot N, Borsotti F, Vincent J,
Ilie S, Truntzer C, Ghiringhelli F, Thibaudin M.
Effect
of radiochemotherapy on peripheral immune response in
glioblastoma.
Cancer
Immunol Immunother. 2024 May 16;73(7):133. doi:
10.1007/s00262-024-03722-5. PMID:
38753169. Observational study. ˍ
Peciu-Florianu I, Vannod-Michel Q, Vauleon E, Bonneterre ME, Reyns
N.
Long term follow-up of patients
with newly diagnosed glioblastoma treated by intraoperative
photodynamic therapy: an update from the INDYGO trial
(NCT03048240).
J
Neurooncol. 2024 May 16. doi:
10.1007/s11060-024-04693-4. PMID:
38753093. Interventional study. ˍ
Hu Y, Zhang K.
Noninvasive assessment
of Ki-67 labeling index in glioma patients based on
multi-parameters derived from advanced MR imaging.
Front
Oncol. 2024 May 17;14:1362990. doi:
10.3389/fonc.2024.1362990. PMID:
38826787. Observational study. ˍ
Huang T, Sun F, Gao K, Wang Y, Zhu G, Chen F.
The
role of Peripheral Inflammatory Markers and Coagulation factors in
patients with CNS immune disease and glioma.
World
Neurosurg. 2024 May 17:S1878-8750(24)00843-X. doi:
10.1016/j.wneu.2024.05.080. PMID:
38763458. Observational study˰
ˍ
Kameda-Smith MM, Green K, Hutton DL, Jeelani NUO, Thompson DNP,
Hargrave D, Aquilina K.
The role of
reoperation in pediatric cerebellar pilocytic astrocytoma.
J
Neurosurg Pediatr. 2024 May 17:1-7. doi:
10.3171/2024.2.PEDS23236. PMID:
38759245. Observational study˰
ˍ
Vogiatzi I, Lama LM, Lehmann A, Rossignoli F, Gettemans J, Shah K.
Allogeneic stem cells engineered to
release interferon β and scFv-PD1 target glioblastoma and
alter the tumor microenvironment.
Cytotherapy.
2024 May 17:S1465-3249(24)00719-9. doi:
10.1016/j.jcyt.2024.05.012. PMID:
38852095. Laboratory investigation. ˍ
*Rosas-Alonso R, Colmenarejo-Fernández J, Pernía O,
Burdiel M, Rodríguez-Antolín C, Losantos-García
I, Rubio T, Moreno-Velasco R, Esteban-Rodríguez I,
Martínez-Marín V, Yubero P, Costa-Fraga N,
Díaz-Lagares A, López-López R, Díaz-Martin
E, García JF, Sánchez CV, Gandía-González
ML, Moreno-Bueno G, de Castro J, de Cáceres II.
Evaluation
of the clinical use of MGMT methylation in extracellular
vesicle-based liquid biopsy as a tool for glioblastoma patient
management.
Sci
Rep. 2024 May 18;14(1):11398. doi:
10.1038/s41598-024-62061-8. PMID:
38762534. Laboratory investigation. ˍ
*Zhang Y, Xi K, Fu Z, Zhang Y, Cheng B, Feng F, Dong Y, Fang Z,
Zhang Y, Shen J, Wang M, Han X, Geng H, Sun L, Li X, Chen C, Jiang
X, Ni S.
Stimulation of tumoricidal
immunity via bacteriotherapy inhibits glioblastoma relapse.
Nat
Commun. 2024 May 18;15(1):4241. doi:
10.1038/s41467-024-48606-5. PMID:
38762500. Laboratory investigation. ˍ
Blakstad H, Mendoza Mireles EE, Kierulf-Vieira KS, Singireddy D,
Mdala I, Heggebø LC, Magelssen H, Sprauten M, Johannesen
TB, Leske H, Niehusmann P, Skogen K, Helseth E, Emblem KE, Vik-Mo
EO, Brandal P.
The impact of cancer
patient pathway on timing of radiotherapy and survival: a cohort
study in glioblastoma patients.
J
Neurooncol. 2024 May 19. doi:
10.1007/s11060-024-04709-z. PMID:
38762830. Observational study. ˍ
Huang
J, Campian JL, DeWees TA, Skrott Z, Mistrik M, Johanns TM, Ansstas
G, Butt O, Leuthardt E, Dunn GP, Zipfel GJ, Osbun JW, Abraham C,
Badiyan S, Schwetye K, Cairncross JG, Rubin JB, Kim AH, Chheda MG.
A
phase 1/2 study of disulfiram and copper with concurrent radiation
therapy and temozolomide for patients with newly diagnosed
glioblastoma.
Int
J Radiat Oncol Biol Phys.
2024 May 19:S0360-3016(24)00660-6. doi:
10.1016/j.ijrobp.2024.05.009. PMID:
38768767. Interventional study˰ ˍ
Hudelist B, Elia A, Roux A, Paun L, Schumacher X, Hamza M, Demasi
M, Moiraghi A, Dezamis E, Chrétien F, Benzakoun J,
Oppenheim C, Zanello M, Pallud J.
Impact
of frailty on survival glioblastoma, IDH-wildtype patients.
J
Neurooncol. 2024 May 19. doi:
10.1007/s11060-024-04699-y. PMID:
38762828. Observational study˰
ˍ
Picca A, Di Stefano AL, Savatovsky J, Ducray F, Chinot O, Moyal
EC, Augereau P, Le Rhun E, Schmitt Y, Rousseaux N, Yepnang AMM,
Estellat C, Charbonneau F, Letourneur Q, Branger DF, Meyronet D,
Fardeau C, Mokhtari K, Bielle F, Iavarone A, Sanson M.
TARGET:
A phase I/II open-label multicenter study to assess safety and
efficacy of fexagratinib in patients with relapsed/refractory FGFR
fusion-positive glioma.
Neurooncol
Adv. 2024 May 20;6(1):vdae068. doi:
10.1093/noajnl/vdae068. PMID:
38813112.
Interventional study. ˍ
Chen
JJ, Vincent MY, Shepard D, Peereboom D, Mahalingam D, Battiste J,
Patel MR, Juric D, Wen PY, Bullock A, Selfridge JE, Pant S, Liu J,
Li W, Fyfe S, Wang S, Zota V, Mahoney J, Watnick RS, Cieslewicz M,
Watnick J.
Phase
1 dose expansion and biomarker study assessing first-in-class
tumor microenvironment modulator VT1021 in patients with advanced
solid tumors.
Commun
Med (Lond).
2024 May 21;4(1):95. doi: 10.1038/s43856-024-00520-z. PMID:
38773224. Interventional study. ˍ
Lin
FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B,
Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF,
Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B,
Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G,
Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE,
Rooney CM, Omer B.
Phase
I Trial of GD2.CART Cells Augmented With Constitutive
Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS
Tumors.
J
Clin Oncol.
2024 May 21:JCO2302019. doi:
10.1200/JCO.23.02019. PMID:
38771986. Interventional study. ˍ
Adolph JE, Fleischhack G, Tschirner S, Rink L, Dittes C, Mikasch
R, Dammann P, Mynarek M, Obrecht-Sturm D, Rutkowski S, Bison B,
Warmuth-Metz M, Pietsch T, Pfister SM, Pajtler KW, Milde T,
Kortmann RD, Dietzsch S, Timmermann B, Tippelt S; German GPOH
HIT-Network.
Radiotherapy for
Recurrent Medulloblastoma in Children and Adolescents: Survival
after Re-Irradiation and First-Time Irradiation.
Cancers
(Basel). 2024 May 22;16(11):1955. doi:
10.3390/cancers16111955. PMID:
38893076. Observational study. ˍ
Donzé C, Revon-Rivière G, Pondrom M, Verschuur A,
Leblond P, André N.
Retrospective
experience of children with relapsed brain tumors treated with
oral combination of axitinib and metronomic etoposide.
Pediatr
Blood Cancer. 2024 May 22:e31076. doi:
10.1002/pbc.31076. PMID:
38778441. Observational
study. ˍ
Kim
N, Lee J, Shin H, Shin J, Nam DH, Lee JI, Seol HJ, Kong DS, Choi
JW, Chong K, Lee WJ, Chang JH, Kang SG, Moon JH, Cho J, Lim DH,
Yoon HI.
Nomogram
for radiation-induced lymphopenia in patients receiving
intensity-modulated radiotherapy based-chemoradiation therapy for
newly diagnosed glioblastoma: A multi-institutional study.
Clin
Transl Radiat Oncol.
2024 May 22;47:100799. doi:
10.1016/j.ctro.2024.100799. PMID:
38884005. Observational study. ˍ
Jiang MQ, Yu SP, Estaba T, Choi E, Berglund K, Gu X, Wei L.
Reprogramming Glioblastoma Cells into
Non-Cancerous Neuronal Cells as a Novel Anti-Cancer Strategy.
Cells.
2024 May 23;13(11):897. doi:
10.3390/cells13110897. PMID:
38891029. Laboratory investigation. ˍ
Ono
T, Suzuki H, Nanjo H, Shimizu H.
Clinical
Course after Carmustine Wafer Implantation for Newly Diagnosed
Adult-type Diffuse Gliomas; A controlled propensity matched
analysis of a single center cohort.
J
Neurooncol.
2024 May 23. doi:
10.1007/s11060-024-04679-2. PMID:
38780714. Observational study˰ ˍ
*Pham
HN, Goldberg RJ, Pham LQ, Nguyen HL, Pham DA, Mai LTT, Phung TL,
Hung DQ, Dong HV, Duong HD.
Maternal
and Perinatal Factors Associated With Childhood Brain Tumors: A
Case-Control Study in Vietnam.
Cancer
Control.
2024 May 23;31:10732748241258602. doi:
10.1177/10732748241258602. PMID:
38783766. Observational study. ˍ
Tamas
V, Hollenbach K, Saleh F, Crawford J, Gutglass DJ.
Clinical
Characteristics and Delayed Diagnosis of Pediatric Patients
Presenting to the Emergency Department With a Newly Diagnosed
Central Nervous System Tumor: A Single Institutional Experience.
Pediatr
Emerg Care.
2024 May 23. doi:
10.1097/PEC.0000000000003227. PMID:
38776448. Observational study˰ ˍ
Tanaka R, Mrachek K, Arocho-Quinones E, Carlberg VM, Smith C,
Kurzrock R, Deshmukh T.
Dabrafenib for
Pilocytic Astrocytoma With BRAF
V599ins.
JCO
Precis Oncol. 2024 May 23;8:e2400055. doi:
10.1200/PO.24.00055. PMID:
38781546. Case report˰
ˍ
*Onubogu U, Gatenbee CD, Prabhakaran S, Wolfe K, Oakes B, Salatino
R, Vaubel R, Szentirmai O, Anderson ARA, Janiszewska M.
Spatial
analysis of recurrent glioblastoma reveals perivascular niche
organization.
JCI
Insight. 2024 May 23:e179853. doi:
10.1172/jci.insight.179853. PMID:
38805346. Laboratory investigation. ˍ
Fadel HA, Pawloski JA, Anzalone AJ, Haider S, Schultz LR, Kalkanis
SN, Robin AM, Lee IY.
Laser
interstitial thermal therapy for first-line treatment of insular
glioma.
J
Neurosurg. 2024 May 24:1-12. doi:
10.3171/2024.2.JNS232807. PMID:
38788240. Observational
study˰ ˍ
Redhu
R, Pavithra HN.
Spinal
extradural meningioma: Report of two cases.
J
Craniovertebr Junction Spine.
2024 May 24;15(2):254-257. doi:
10.4103/jcvjs.jcvjs_12_24. PMID:
38957768. Case report. ˍ
Xiao Y, Li M, Wang X, Tan J, Qin C, Liu Q.
Fluorescein-guided
surgery in high-grade gliomas: focusing on the eloquent and
deep-seated areas.
J
Cancer Res Clin Oncol. 2024 May 25;150(5):274. doi:
10.1007/s00432-024-05796-1. PMID:
38795238.
Observational study. ˍ
Cadrien C, Sharma S, Lazen P, Licandro R, Furtner J, Lipka A,
Niess E, Hingerl L, Motyka S, Gruber S, Strasser B, Kiesel B,
Mischkulnig M, Preusser M, Roetzer-Pejrimovsky T, Wöhrer A,
Weber M, Dorfer C, Trattnig S, Rössler K, Bogner W, Widhalm
G, Hangel G.
7 Tesla magnetic
resonance spectroscopic imaging predicting IDH status and glioma
grading.
Cancer
Imaging. 2024 May 27;24(1):67. doi:
10.1186/s40644-024-00704-9. PMID:
38802883.
Observational study. ˍ
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M,
Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay
R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M,
Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C,
Ducray F; POLA Network.
Olaparib in
recurrent isocitrate dehydrogenase mutant high-grade glioma: A
phase 2 multicenter study of the POLA Network.
Neurooncol
Adv. 2024 May 27;6(1):vdae078. doi:
10.1093/noajnl/vdae078. PMID:
38855053. Interventional study. ˍ
Lee Y, Park CK, Park SH.
Prognostic
Impact of TERT
Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021
Criteria.
Cancers
(Basel). 2024 May 27;16(11):2032. doi:
10.3390/cancers16112032. PMID:
38893152. Observational study. ˍ
*Webb LM, Neth BJ, Raghunathan A, Greipp PT, Ida CM, Carabenciov
ID, Ruff MW.
A Case of Long-Term
Survival After Glioblastoma, IDH-Wild Type.
Neurologist.
2024 May 27. doi:
10.1097/NRL.0000000000000564. PMID:
38797928. Case report˰
ˍ
Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R,
Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC,
Sahm K, Oster C, Kebir S, Hambsch P, Pietsch T, Bisdas S, Platten
M, Glas M, Seidel C, Herrlinger U, Hölzel M.
L-RNA
aptamer-based CXCL12 inhibition combined with radiotherapy in
newly-diagnosed glioblastoma: dose escalation of the phase I/II
GLORIA trial.
Nat
Commun. 2024 May 28;15(1):4210. doi:
10.1038/s41467-024-48416-9. PMID:
38806504.
Interventional study. ˍ
Hua W, Zhang W, Brown H, Wu J, Fang X, Shahi M, Chen R, Zhang H,
Jiao B, Wang N, Xu H, Fu M, Wang X, Zhang J, Zhang X, Wang Q, Zhu
W, Ye D, Garcia DM, Chaichana K, Cooks RG, Ouyang Z, Mao Y,
Quinones-Hinojosa A.
Rapid detection
of IDH mutations in gliomas by intraoperative mass spectrometry.
Proc Natl Acad Sci U S A. 2024 May
28;121(23):e2318843121. doi: 10.1073/pnas.2318843121? PMID:
38805277. Observational
study. ˍ
Reynolds S.
Tovorafenib Approved for
Some Children with Low-Grade Glioma.
Cancer
Curr Blog. 2024 May 28. News. ˍ
Chang WC, Hsieh TC, Hsu WL, Chang FL, Tsai HR, He MS.
Diabetes
and further risk of cancer: a nationwide population-based study.
BMC
Med. 2024 May 29;22(1):214. doi:
10.1186/s12916-024-03430-y. PMID:
38807177.
Observational study. ˍ
Chen M, Xu X, Wang F, Xu X.
Development
of predicting nomograms for diffuse astrocytoma and anaplastic
astrocytoma: a study based on the SEER database.
World
Neurosurg. 2024 May 29:S1878-8750(24)00910-0. doi:
10.1016/j.wneu.2024.05.147. PMID:
38821404. Observational study˰
˰
Pham LC, Weller L, Gann CN, Schumacher KM, Vlassak S, Swanson T,
Highsmith K, O'Brien BJ, Nash S, Aaroe A, de Groot JF, Majd NK.
Prolonged complete response to
adjuvant tepotinib in a patient with newly diagnosed disseminated
glioblastoma harboring mesenchymal-epithelial transition
fusion.
Oncologist.
2024 May 30:oyae100. doi:
10.1093/oncolo/oyae100. PMID:
38815166. Case report. ˍ
Upadhyay R, Klamer B, Matsui J, Chakravarthy VB, Scharschmidt T,
Yeager N, Setty BA, Cripe TP, Roberts RD, Aldrink JH, Singh R,
Raval RR, Palmer JD, Baliga S.
Disease
Control and Toxicity Outcomes after Stereotactic Ablative
Radiation Therapy for Recurrent and/or Metastatic Cancers in
Young-Adult and Pediatric Patients.
Cancers
(Basel). 2024 May 30;16(11):2090. doi:
10.3390/cancers16112090. PMID:
38893209. Observational study. ˍ
Cai L, Liu Y, Sun T.
A case report
with discussion on the treatment of giant cell glioblastoma.
Asian
J Surg. 2024 May 31:S1015-9584(24)01019-4. doi:
10.1016/j.asjsur.2024.05.129. PMID:
38824015. Case report. ˍ